Shares of Allergan plc (NYSE:AGN) have been given a consensus recommendation of “Buy” by the twenty research firms that are presently covering the company. Five analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $265.64.

A number of equities analysts recently weighed in on the company. Sanford C. Bernstein set a $275.00 price objective on Allergan plc and gave the company a “buy” rating in a report on Sunday, December 25th. Citigroup Inc reissued a “focus list” rating and set a $261.27 price objective (up from $184.50) on shares of Allergan plc in a report on Friday. Royal Bank of Canada set a $279.00 price objective on Allergan plc and gave the company a “buy” rating in a report on Wednesday, April 12th. Vetr cut Allergan plc from a “hold” rating to a “sell” rating and set a $211.12 price objective on the stock. in a report on Thursday, January 5th. Finally, Deutsche Bank AG raised their price objective on Allergan plc from $262.00 to $265.00 and gave the company a “buy” rating in a report on Tuesday, March 28th.

ILLEGAL ACTIVITY WARNING: “Analysts Set Allergan plc (AGN) Price Target at $270.78” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another website, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/04/21/allergan-plc-agn-receives-270-78-average-price-target-from-analysts-updated.html.

In other news, Director Paul Bisaro sold 70,000 shares of the business’s stock in a transaction on Thursday, March 2nd. The stock was sold at an average price of $246.68, for a total value of $17,267,600.00. Following the completion of the transaction, the director now owns 274,226 shares in the company, valued at $67,646,069.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.27% of the stock is owned by insiders.



Hedge funds have recently bought and sold shares of the stock. Norges Bank purchased a new stake in Allergan plc during the fourth quarter worth approximately $682,333,000. Appaloosa LP boosted its stake in Allergan plc by 249.8% in the fourth quarter. Appaloosa LP now owns 4,261,406 shares of the company’s stock worth $894,938,000 after buying an additional 3,043,097 shares during the period. Edgewood Management LLC purchased a new stake in Allergan plc during the fourth quarter worth approximately $530,518,000. Baupost Group LLC MA boosted its stake in Allergan plc by 71.5% in the fourth quarter. Baupost Group LLC MA now owns 3,432,603 shares of the company’s stock worth $720,881,000 after buying an additional 1,430,625 shares during the period. Finally, Lazard Asset Management LLC boosted its stake in Allergan plc by 53.8% in the third quarter. Lazard Asset Management LLC now owns 3,017,790 shares of the company’s stock worth $695,025,000 after buying an additional 1,055,305 shares during the period. Institutional investors own 86.40% of the company’s stock.

Allergan plc (NYSE:AGN) traded down 0.67% during midday trading on Tuesday, hitting $236.35. 1,690,925 shares of the stock were exchanged. The company has a 50 day moving average price of $238.85 and a 200 day moving average price of $221.59. The firm has a market capitalization of $79.23 billion, a price-to-earnings ratio of 6.19 and a beta of 1.07. Allergan plc has a one year low of $184.50 and a one year high of $261.27.

Allergan plc (NYSE:AGN) last announced its quarterly earnings data on Wednesday, February 8th. The company reported $3.90 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.76 by $0.14. The company had revenue of $3.86 billion for the quarter, compared to analysts’ expectations of $3.77 billion. Allergan plc had a return on equity of 7.21% and a net margin of 100.04%. Allergan plc’s revenue for the quarter was up 7.1% compared to the same quarter last year. During the same period last year, the firm posted $3.41 EPS. Equities analysts anticipate that Allergan plc will post $16.03 EPS for the current year.

About Allergan plc

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

5 Day Chart for NYSE:AGN

Receive News & Stock Ratings for Allergan plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan plc and related stocks with our FREE daily email newsletter.